ImageneBio, Inc. (IMA)

ImageneBio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-20.33	-36.57	-21.15
Depreciation & Amortization	0.89	1.53	3.1
Loss (Gain) From Sale of Assets	1.27	1.27	0
Loss (Gain) From Sale of Investments	-	-	-0.14
Other Operating Activities	0.12	13.97	-0.94
Change in Accounts Payable	2.04	-0.52	3.89
Change in Unearned Revenue	-0.14	0.51	-0.14
Change in Other Net Operating Assets	-3.29	-1.5	-2.85
Operating Cash Flow	-19.38	-21.32	-18.23
Capital Expenditures	-	-	-0.31
Sale of Property, Plant & Equipment	0.97	0.97	0
Investment in Securities	-	10.15	-10.15
Investing Cash Flow	0.97	11.12	-10.45
Short-Term Debt Issued	-	7.5	-
Total Debt Issued	7.5	7.5	-
Net Debt Issued (Repaid)	7.5	7.5	-
Issuance of Common Stock	0.05	-	0.15
Other Financing Activities	-0.61	-0.59	-
Financing Cash Flow	6.93	6.91	0.15
Foreign Exchange Rate Adjustments	-0.01	0.09	-0.15
Net Cash Flow	-11.48	-3.2	-28.69
Free Cash Flow	-19.38	-21.32	-18.54
Free Cash Flow Margin	-450.79%	-609.11%	-232.83%
Free Cash Flow Per Share	-0.04	-0.05	-0.06
Cash Income Tax Paid	0.22	0.22	0.12
Levered Free Cash Flow	-	-21.2	-
Unlevered Free Cash Flow	-	-21.2	-
Change in Working Capital	-1.39	-1.52	0.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q